Correction to Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors

This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Addition/Correction Cite This: J. Med. Chem. XXXX, XXX, XXX−XXX

pubs.acs.org/jmc

Correction to Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors Jeffrey T. Bagdanoff, Zhouliang Chen, Michael Acker, Ying-Nan Chen, Homan Chan, Michael Dore, Brant Firestone, Michelle Fodor, Jorge Fortanet, Murphy Hentemann, Mitsunori Kato, Robert Koenig, Laura R. LaBonte, Shumei Liu, Movarid Mohseni, Rukundo Ntaganda, Patrick Sarver, Michael D. Shultz, Troy Smith, Martin Sendzik, Travis Stams, Stan Spence, Christopher Towler, Hongyun Wang, Ping Wang, Sarah L. Williams, and Matthew J. LaMarche*

J. Med. Chem. Downloaded from pubs.acs.org by 95.85.68.74 on 03/22/19. For personal use only.

J. Med. Chem. 2019, 62 (4), 1781−1792. DOI: 10.1021/acs.jmedchem.8b01725 Page 1781. Michael D. Shultz† should be listed as an additional coauthor, and the order of the authors are as listed above in the byline. † Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts, 02139, United States.

© XXXX American Chemical Society

A

DOI: 10.1021/acs.jmedchem.9b00435 J. Med. Chem. XXXX, XXX, XXX−XXX